Biomarkers and The Adoption Cycle: Where are we now?

This week we introduced the correlation between a company’s biomarker coverage in their clinical trial pipeline and their Likelihood of Approval. After showing correlation between approval and biomarker use, we wanted to know more about a company’s biomarker use...

Precision Medicine Focus: Psychiatric Biomarkers

An interesting article was published today in the Journal of Precision Medicine describing the importance of testing psychiatry patients for mutations in two companion diagnostic biomarkers, CYP2D6 and CYP2C19. These are indeed important biomarkers for safe...

Lawsuit a Catalyst for LDT Regulation Progress?

We have written extensively about health system regulation in this blog, with a keen interest in how LDT regulation will shake out.  In our other blog we’ve even argued strongly for caution in LDT regulation, primarily to avoid stifling innovation.  However, our...